Company Information

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Our proprietary Cabaletta Approach to B cell Ablation (CABA^®) platform is designed to provide durable, potentially curative, responses with one-time administration, with the possibility of eliminating the need for chronic immune suppressive therapies. We believe the CABA™ platform has potential applicability across a broad range of autoimmune diseases. It encompasses two strategies: the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach as well as our initial Chimeric AutoAntibody Receptor T (CAART) approach. Our lead CARTA candidate, CABA-201, is an investigational 4-1BB-containing CD19-CAR T cell therapy based on a clinically evaluated fully human CD19 binder. CABA-201 is currently under development for systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis as well as other autoimmune diseases with high unmet need. Through our initial CAART platform, we are developing our clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. Our goal is to leverage our team’s expertise in autoimmunity and T cell therapy and our network of collaborators to rapidly develop and launch our portfolio of engineered T cell therapy candidates to transform the treatment of autoimmune diseases.